« Return to News | Clinical Intelligence

FDA clears IND for treatment of acute seizures

Friday, February 10, 2012 12:06 PM

The FDA has cleared Neurelis’ Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1, a diazepam nasal spray for the treatment of acute breakthrough seizures, according to Neurelis.

Following initial pre-IND discussions with FDA in late 2011, Neurelis filed the IND based on the encouraging human pharmacokinetic results seen when comparing absolute bioavailability of NRL-1 relative to intravenous diazepam administration in healthy subjects.  In the IND submission, Neurelis formalized plans for the remaining clinical and non-clinical requirements the FDA agreed to in the pre-IND discussions that will support the submission for marketing approval.

"We are encouraged with our interactions with the FDA and the formalization of our development plan for NRL-1.  The acceptance of the IND is a significant step in advancing the development of this important therapy," said David F. Hale, chairman of Neurelis. 

"We believe that NRL-1 has demonstrated a pharmacokinetic profile and bioavailability which has not been seen with previous attempts at the intranasal delivery of benzodiazepines,” he said. “With the successful development of NRL-1 and approval from the FDA and other regulatory agencies, we look forward to making this product available to those patients who have epilepsy and suffer from acute repetitive seizures."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.